VCEL logo

Vericel Corporation (VCEL)

$57.88

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on VCEL

Market cap

$2.95B

EPS

0.65

P/E ratio

83.5

Price to sales

6.7

Dividend yield

--

Beta

1.084549

Price on VCEL

Previous close

$57.48

Today's open

$57.48

Day's range

$57.32 - $58.68

52 week range

$28.95 - $59.75

Profile about VCEL

CEO

Dominick Colangelo

Employees

398

Headquarters

Burlington, MA

Exchange

NASDAQ Global Market

Shares outstanding

51029770

Issue type

Common Stock

VCEL industries and sectors

Healthcare

Biotechnology & Life Sciences

News on VCEL

Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026

BURLINGTON, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Stephens Annual Investment Conference at 4:30 p.m. ET (3:30 p.m. CT) on Wednesday, November 18, 2026.

news source

GlobeNewsWire • Nov 13, 2026

news preview

Earnings Estimates Moving Higher for Vericel (VCEL): Time to Buy?

Vericel Corporation (VCEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

news source

Zacks Investment Research • Nov 10, 2026

news preview

Vericel Q3 Earnings Call Highlights

Vericel NASDAQ: VCEL raised its full-year revenue and profitability outlook after third-quarter sales rose 26%, led by growth in its MACI cartilage repair product and a record quarter for its burn care business.

news source

MarketBeat • Nov 6, 2026

news preview

Vericel Corporation (VCEL) Q3 2026 Earnings Call Transcript

Vericel Corporation ( VCEL ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Eric Burns - Vice President of Finance & Investor Relations Dominick C. Colangelo - CEO, President & Director Joseph Mara - CFO & Treasurer Conference Call Participants Joshua Jennings - TD Cowen, Research Division Caitlin Roberts - Canaccord Genuity Corp., Research Division Richard Newitter - Truist Securities, Inc., Research Division Ryan Zimmerman - BTIG, LLC, Research Division Samuil-Hrabar Gatev - Leerink Partners LLC, Research Division Mason Carrico - Stephens Inc., Research Division Presentation Operator Good day, and welcome to the Vericel Corporation Third Quarter 2026 Earnings Call.

news source

Seeking Alpha • Nov 6, 2026

news preview

Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

Total Revenue Growth of 26% to $85.4 Million Net Income Increased 179% to $14.2 Million Adjusted EBITDA Margin of 30% Raised Full-Year Revenue Guidance to $344 to $346 Million and Adjusted EBITDA Margin Guidance to 28% Conference Call Today at 8:30am Eastern Time

news source

GlobeNewsWire • Nov 5, 2026

news preview

Vericel Corporation (VCEL) Beats Q3 Earnings and Revenue Estimates

Vericel Corporation (VCEL) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.1 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026

BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its third quarter 2026 financial results on Thursday, November 5, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

news source

GlobeNewsWire • Oct 22, 2026

news preview

Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

news source

Seeking Alpha • Sep 16, 2026

news preview

Vericel: MACI And Regenerative Knee Cartilage

Vericel's MACI already has an established commercial base, which I think gives them an easier path for future growth. MACI's arthroscopic delivery could also help it expand among surgeons. That's why VCEL's Burlington added capacity is timely if demand indeed increases. I also like that VCEL's recently gained BARDA contract helps with its Burn Care business. VCEL also has a potential UK launch and an ankle indication in the works.

news source

Seeking Alpha • Sep 15, 2026

news preview

Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026

BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15th, 2026.

news source

GlobeNewsWire • Sep 8, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Vericel Corporation

Open an M1 investment account to buy and sell Vericel Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in VCEL on M1